Patient Rating:

4.8 out of 5

51 Patient Ratings
26 Patient Comments

Ahmad Halwani, M.D.

Patient Rating:

4.8 out of 5

51 Patient Ratings
26 Patient Comments

Specialties

Languages

  • Arabic
  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-2626 Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Malignant
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Dr. Halwani specializes in the treatment of blood related cancers such as lymphoma and leukemia. His main clinical operation is at the University of Utah Huntsman Cancer Institute Clinic 2B. He also sees patients at the George E. Wahlen Veteran's Medical Center.

For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 585-6906.

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification American Board of Allergy & Immunology
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.8
My confidence in care provider
4.8
Time care provider spent with me
4.8
Care provider spoke using clear language
4.7
Care provider's effort to include me in decisions
4.7
Care provider's concern for questions & worries
4.8
Care provider's explanation of condition/problem
4.8
Wait time at clinic
4.3
Care provider's friendliness and courtesy
4.8

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

November 22, 2014

Dr. Halwani is such a caring and knowledgable Oncologist. As always, he is very thorough in discussing all aspects of my husband's condition. We trust him completely.

November 18, 2014

My doctor was awesome, he was very kind and really explained everything to me, and answered all of my questions.

October 12, 2014

My care could not have been better.

September 23, 2014

Thank you all for being so concerned for me and helping get started on treatment. You have helped me immensely!

August 08, 2014

The DR was assed a lot of appropriate questions to help determine what was going on & he seemed to really care about my health

August 04, 2014

I love Dr. Halwani he is very caring and gives me all the time I need. And Renee' she makes sure I'm doing what I need to do to take care of myself, I feel their concern for me.

August 03, 2014

dr Halwani is amazing!

July 17, 2014

Everyone was amazing. Dr. Halwani is amazing!!

May 25, 2014

Everyone but especially Dr. Halwani treated my in an amazing manner on this visit. I was moved to tears by the time and attention he gave to me!

March 23, 2014

This has to be the best experience I have ever had at any medical facility.

March 01, 2014

All of my experiences have been exceptional.

February 21, 2014

The blood results took a week to find out. That was longer than I was told but other than that worrying waiting time all was super!

February 02, 2014

I was very satisfied with the. care and consideration I received.

January 20, 2014

Fantastic people

January 17, 2014

My whole experience was uplifting and reassuring. Dr. Halwani was amazing.

November 27, 2013

I don't feel I relate well with his communication style. I feel someone more personable would be a better fit for me. he explains himself well but I feel he is missing the personality.

July 29, 2013

Most of the information I received during my visit was from the nurse practitioner. They're loaded with clinical information and I usually spend the bulk of my time with them. The doctor basically looks at my labs and wonders when I'll be classified CLL or when I'll need drugs and medical procedures. There are no suggestions on how to sustain my current quality of life during this waiting period. In particular, there's no discussion on the effect of diet. Why are they not versed on that topic? I guess my belief is that a primary goal of the providers is to get as many of us into treatment and to then keep us there for as long as possible, and to profit to the maximum extent.

June 24, 2013

I ask many questions and they are always great about discussing them with me. The problem is that I probably ask to many questions, so I actually feel sorry for your people, but they are always great with me.

May 07, 2013

Everyone is very knowledgeable

April 01, 2013

Very positive and made us feel at ease

January 09, 2013

I am very pleased to be under the care of Dr. Halwani. I feel very confident about his expertise regarding my condition.

December 24, 2012

The improvement over my past oncologist at a different facility is very comforting.

December 24, 2012

did not recommend treatment just said wait

December 02, 2012

Very good care. But concerned that we had came in for a 2nd opinion and I guess we were not clear on the past visit because we were under the impression we needed to get a biopsy to start chemo treatment and was informed we did not need the chemo just yet and don't know if the bone marrow biopsy was really needed. And again I believe this comes back to the schedulers communicating with the Doctors.

June 15, 2012

I am pleased with all the staff. they seem to be happy and easy to work with.

May 11, 2012

I'm serious about the marks, not only very good, but at times pleasant

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification American Board of Allergy & Immunology
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 433-4334 Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Ahmad S. Halwani, M.D. is a Clinical Instructor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. Dr. Halwani also has an appointment at the George E. Whalen Salt Lake City Veteran's Affairs Medical Center, where he started a Leukemia-Lymphoma clinic, the Salt Lake City VA's first subspecialty oncology clinic. Specializing in the treatment of blood related cancers such as lymphoma and leukemia, his main clinical operation is at the University of Utah Huntsman Cancer Institute Clinic 2B. He is an investigator at the Huntsman Cancer Institute and a member of the Experimental Therapeutics program.

Dr. Halwani's research interests include immunotherapy for hematologic malignancies, as well as understanding the interactions between the immune system and cancer. Immunotherapy for treatment of cancer is a rapidly expanding field. Novel antibodies target various cancer associated antigens. In addition, new immunomodulators target the microenvironment around the cancer cells. As the understanding of regulatory immune mechanisms evolves, T-cell costimulation inhibition is an exciting new modality that has shown exciting results in treatment of multiple cancers. As a clinical and translational investigator, Dr. Halwani’s research focuses on design and implementation of clinical trials that bring recent advances in immunotherapy from bench to bedside. He is principle investigator on a number of clinical trials that focus on treatment of hematologic malignancies with immune therapies, including novel antibodies with augmented mechanisms of action, antibody-drug conjugates, and T-cell costimulation inhibitors. His clincal trial portfolio ranges the entire spectrum of clinical trials, from phase I to randomized phase III trials.

He received his B.S. in Biology, with High Distinction, from the American University of Beirut in Lebanon, followed by his medical degree also at the American University of Beirut. Dr. Halwani next completed his residency in Internal Medicine at the University of Iowa Hospitals and Clinics, then two consecutive Fellowships, also at Iowa: in Allergy and Immunology and then in Medical Oncology. Dr. Halwani is board certified in Internal Medicine, Medical Oncology, and in Allergy and Immunology.

Education

Education History

Type School Degree
Fellowship University of Iowa Hospitals & Clinics
Medical Oncology
Fellow
Fellowship University of Iowa Hospitals & Clinics
Allergy and Immunology
Fellow
Residency University of Iowa Hospitals & Clinics
Internal Medicine
Resident
Professional Medical American University of Beirut
Medicine
M.D.
Undergraduate American University of Beirut
Biology with High Distinction
B.S.
Graduate Training University of Utah
Clinical Investigation
M.S.C.I

Publications

Selected Provider Publications

Journal Article

  1. Ontiveros, Evelena, Halwani, Ahmad (03/07/2014). A New Model of LMP1-MYC Interaction in B Cell Lymphoma. Doi:10.3109/10428194.2014.900762. Leuk Lymphoma.
  2. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (01012013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436, 660-665.
  3. Halwani AS, Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther, 11(3), 443-55.
  4. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res, 14(20), 6697-703.

Abstract

  1. Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (01012014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
  2. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (01012014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL) [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
  3. Halwani A, Stunz S, Hu L, Janz S, Bishop G (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; University of Iowa Carver College of Medicine, College of Pharmacy, College of Public Health, Institute for Clinical and Translational Science and VA Health System Research Week [Abstract].
  4. Halwani A, Ballas Z (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting [Abstract]. 123(2, Supplement 1), S89.

Poster

  1. Halwani A, AbuHejleh T, Deutsch J, Engelman E, Swift J, Hohl R, Hamarneh I, Smith B, Milhem M (October 26-29, 2011). A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy And A Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. (CTOS 2011- Poster #97). Poster session presented at Connective Tissue Oncology Society.

Clinical Trials

Video & News